nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Abstract #10: Amyloid Precursor Protein Secretases As Therapeutic Targets for Spinal Cord Injury
|
Pajoohesh-Ganji, Ahdeah |
|
2010 |
7 |
3 |
p. 331- 1 p. |
artikel |
2 |
Abstract #10: Amyloid Precursor Protein Secretases As Therapeutic Targets for Spinal Cord Injury
|
Pajoohesh-Ganji, Ahdeah |
|
|
7 |
3 |
p. 331 |
artikel |
3 |
Abstract #5: A Phase I, Dosage-Escalation Study of Creatine Monohydrate in Subjects with Amyotrophic Lateral Sclerosis
|
Atassi, Nazem |
|
2010 |
7 |
3 |
p. 329- 1 p. |
artikel |
4 |
Abstract #5: A Phase I, Dosage-Escalation Study of Creatine Monohydrate in Subjects with Amyotrophic Lateral Sclerosis
|
Atassi, Nazem |
|
|
7 |
3 |
p. 329 |
artikel |
5 |
Abstract #12: Computerized Essential Tremor Spirography: Development of a Rater-Independent Outcome Measure for Clinical Trials
|
Haubenberger, Dietrich |
|
2010 |
7 |
3 |
p. 332- 1 p. |
artikel |
6 |
Abstract #12: Computerized Essential Tremor Spirography: Development of a Rater-Independent Outcome Measure for Clinical Trials
|
Haubenberger, Dietrich |
|
|
7 |
3 |
p. 332 |
artikel |
7 |
Abstract #3: Converting from CIS to Definite Multiple Sclerosis: An Imaging Based Predictive Model
|
Goldberg-Zimring, Daniel |
|
2010 |
7 |
3 |
p. 328-329 2 p. |
artikel |
8 |
Abstract #3: Converting from CIS to Definite Multiple Sclerosis: An Imaging Based Predictive Model
|
Goldberg-Zimring, Daniel |
|
|
7 |
3 |
p. 328-329 |
artikel |
9 |
Abstract #14: Development of a Novel Non-Anxiogenic Broad Spectrum Anti-Emetic
|
Alexander, Elaine |
|
2010 |
7 |
3 |
p. 332-333 2 p. |
artikel |
10 |
Abstract #14: Development of a Novel Non-Anxiogenic Broad Spectrum Anti-Emetic
|
Alexander, Elaine |
|
|
7 |
3 |
p. 332-333 |
artikel |
11 |
Abstract #2: Diffusion Tensor Imaging As a Neuroprotection Outcome Metric in Multiple Sclerosis: Clinical Trial Sample Size Estimates
|
Fox, Robert J. |
|
2010 |
7 |
3 |
p. 328- 1 p. |
artikel |
12 |
Abstract #2: Diffusion Tensor Imaging As a Neuroprotection Outcome Metric in Multiple Sclerosis: Clinical Trial Sample Size Estimates
|
Fox, Robert J. |
|
|
7 |
3 |
p. 328 |
artikel |
13 |
Abstract #15: Efficacy and Safety of Long-Acting Injectable Paliperidone Palmitate Relative to Long-Acting Injectable Haloperidol, Bromperidol, and Fluphenazine Decanoate for Long-Term Treatment in Patients with Schizophrenia Using Number Needed to Treat and Number Needed to Harm
|
Gopal, Srihari |
|
2010 |
7 |
3 |
p. 333- 1 p. |
artikel |
14 |
Abstract #15: Efficacy and Safety of Long-Acting Injectable Paliperidone Palmitate Relative to Long-Acting Injectable Haloperidol, Bromperidol, and Fluphenazine Decanoate for Long-Term Treatment in Patients with Schizophrenia Using Number Needed to Treat and Number Needed to Harm
|
Gopal, Srihari |
|
|
7 |
3 |
p. 333 |
artikel |
15 |
Abstract #1: EVP-6124 Elicits Pro-Cognitive Effects in Alzheimer's Patients
|
Apter, Jeffrey T. |
|
2010 |
7 |
3 |
p. 328- 1 p. |
artikel |
16 |
Abstract #1: EVP-6124 Elicits Pro-Cognitive Effects in Alzheimer's Patients
|
Apter, Jeffrey T. |
|
|
7 |
3 |
p. 328 |
artikel |
17 |
Abstract #9: Gender Related Outcome Differences after Experimental Mild Traumatic Brain Injury
|
Li, Shihong |
|
2010 |
7 |
3 |
p. 331- 1 p. |
artikel |
18 |
Abstract #9: Gender Related Outcome Differences after Experimental Mild Traumatic Brain Injury
|
Li, Shihong |
|
|
7 |
3 |
p. 331 |
artikel |
19 |
Abstract #4: Global vs. Regional Spinal Cord Atrophy in Multiple Sclerosis
|
Arora, Ashish |
|
2010 |
7 |
3 |
p. 329- 1 p. |
artikel |
20 |
Abstract #4: Global vs. Regional Spinal Cord Atrophy in Multiple Sclerosis
|
Arora, Ashish |
|
|
7 |
3 |
p. 329 |
artikel |
21 |
Abstract #13: Low-Dose Naltrexone's Tolerability and Effects in Fatigued Patients with Parkinson's Disease: An Open-Label Study
|
Guttuso Jr., Thomas |
|
2010 |
7 |
3 |
p. 332- 1 p. |
artikel |
22 |
Abstract #13: Low-Dose Naltrexone's Tolerability and Effects in Fatigued Patients with Parkinson's Disease: An Open-Label Study
|
Guttuso Jr., Thomas |
|
|
7 |
3 |
p. 332 |
artikel |
23 |
Abstract #6: Magnetic Resonance Disease Severity Scale (MRDSS) for Patients with Multiple Sclerosis: A Longitudinal Study
|
Tauhid, Shahamat S. |
|
2010 |
7 |
3 |
p. 329-330 2 p. |
artikel |
24 |
Abstract #6: Magnetic Resonance Disease Severity Scale (MRDSS) for Patients with Multiple Sclerosis: A Longitudinal Study
|
Tauhid, Shahamat S. |
|
|
7 |
3 |
p. 329-330 |
artikel |
25 |
Abstract #16: Optical Coherence Tomography As a Clinical Trial Outcome Measure in Multiple Sclerosis: Implications of Treating On-Study Relapses with Intravenous Methylprednisolone
|
Bermel, Robert |
|
2010 |
7 |
3 |
p. 333- 1 p. |
artikel |
26 |
Abstract #16: Optical Coherence Tomography As a Clinical Trial Outcome Measure in Multiple Sclerosis: Implications of Treating On-Study Relapses with Intravenous Methylprednisolone
|
Bermel, Robert |
|
|
7 |
3 |
p. 333 |
artikel |
27 |
Abstracts from the ASENT 2010 annual meeting March 4–6, 2010
|
Apter, Jeffrey T. |
|
2010 |
7 |
3 |
p. 328-333 |
artikel |
28 |
Abstract #11: The Disruptions to Cognition, Everyday Function, and Quality of Life in Oncology Patients: A Therapeutic Opportunity?
|
Wesnes, Keith Andrew |
|
2010 |
7 |
3 |
p. 331-332 2 p. |
artikel |
29 |
Abstract #11: The Disruptions to Cognition, Everyday Function, and Quality of Life in Oncology Patients: A Therapeutic Opportunity?
|
Wesnes, Keith Andrew |
|
|
7 |
3 |
p. 331-332 |
artikel |
30 |
Abstract #8: Trial Methodology of a Randomized, Double-blind, Parallel-Group Study Evaluating the Clinical Effectiveness of Carisbamate, Topiramate, and Levetiracetam As Adjunctive Treatment of Partial Onset Seizures in Adults
|
Cramer, Joyce |
|
2010 |
7 |
3 |
p. 330-331 2 p. |
artikel |
31 |
Abstract #8: Trial Methodology of a Randomized, Double-blind, Parallel-Group Study Evaluating the Clinical Effectiveness of Carisbamate, Topiramate, and Levetiracetam As Adjunctive Treatment of Partial Onset Seizures in Adults
|
Cramer, Joyce |
|
|
7 |
3 |
p. 330-331 |
artikel |
32 |
Abstract #7: Voxel Based Morphometry with DARTEL in Multiple Sclerosis
|
Ceccarelli, Antonia |
|
2010 |
7 |
3 |
p. 330- 1 p. |
artikel |
33 |
Abstract #7: Voxel Based Morphometry with DARTEL in Multiple Sclerosis
|
Ceccarelli, Antonia |
|
|
7 |
3 |
p. 330 |
artikel |
34 |
Aripiprazole in autism spectrum disorders and fragile X syndrome
|
Erickson, Craig A. |
|
2010 |
7 |
3 |
p. 258-263 |
artikel |
35 |
Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
|
Erickson, Craig A. |
|
2010 |
7 |
3 |
p. 258-263 6 p. |
artikel |
36 |
Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
|
Erickson, Craig A. |
|
|
7 |
3 |
p. 258-263 |
artikel |
37 |
Autism and oxytocin: New developments in translational approaches to therapeutics
|
Green, Joshua J. |
|
2010 |
7 |
3 |
p. 250-257 |
artikel |
38 |
Autism and Oxytocin: New Developments in Translational Approaches to Therapeutics
|
Green, Joshua J. |
|
2010 |
7 |
3 |
p. 250-257 8 p. |
artikel |
39 |
Autism and Oxytocin: New Developments in Translational Approaches to Therapeutics
|
Green, Joshua J. |
|
|
7 |
3 |
p. 250-257 |
artikel |
40 |
Complementary and alternative medicine in autism: An evidence-based approach to negotiating safe and efficacious interventions with families
|
Akins, R. Scott |
|
2010 |
7 |
3 |
p. 307-319 |
artikel |
41 |
Complementary and Alternative Medicine in Autism: An Evidence-Based Approach to Negotiating Safe and Efficacious Interventions with Families
|
Akins, R. Scott |
|
2010 |
7 |
3 |
p. 307-319 13 p. |
artikel |
42 |
Complementary and Alternative Medicine in Autism: An Evidence-Based Approach to Negotiating Safe and Efficacious Interventions with Families
|
Akins, R. Scott |
|
|
7 |
3 |
p. 307-319 |
artikel |
43 |
Contents
|
|
|
2010 |
7 |
3 |
p. ii-iii nvt p. |
artikel |
44 |
Contents
|
|
|
|
7 |
3 |
p. ii-iii |
artikel |
45 |
Editorial Board
|
|
|
2010 |
7 |
3 |
p. i- 1 p. |
artikel |
46 |
Editorial Board
|
|
|
|
7 |
3 |
p. i |
artikel |
47 |
Fragile X: Leading the way for targeted treatments in autism
|
Wang, Lulu W. |
|
2010 |
7 |
3 |
p. 264-274 |
artikel |
48 |
Fragile X: Leading the Way for Targeted Treatments in Autism
|
Wang, Lulu W. |
|
2010 |
7 |
3 |
p. 264-274 11 p. |
artikel |
49 |
Fragile X: Leading the Way for Targeted Treatments in Autism
|
Wang, Lulu W. |
|
|
7 |
3 |
p. 264-274 |
artikel |
50 |
Immune dysfunction in autism: A pathway to treatment
|
Careaga, Milo |
|
2010 |
7 |
3 |
p. 283-292 |
artikel |
51 |
Immune Dysfunction in Autism: A Pathway to Treatment
|
Careaga, Milo |
|
2010 |
7 |
3 |
p. 283-292 10 p. |
artikel |
52 |
Immune Dysfunction in Autism: A Pathway to Treatment
|
Careaga, Milo |
|
|
7 |
3 |
p. 283-292 |
artikel |
53 |
Immune therapy in autism: Historical experience and future directions with immunomodulatory therapy
|
Chez, Michael G. |
|
2010 |
7 |
3 |
p. 293-301 |
artikel |
54 |
Immune Therapy in Autism: Historical Experience and Future Directions with Immunomodulatory Therapy
|
Chez, Michael G. |
|
2010 |
7 |
3 |
p. 293-301 9 p. |
artikel |
55 |
Immune Therapy in Autism: Historical Experience and Future Directions with Immunomodulatory Therapy
|
Chez, Michael G. |
|
|
7 |
3 |
p. 293-301 |
artikel |
56 |
Improving the prediction of response to therapy in autism
|
Bent, Stephen |
|
2010 |
7 |
3 |
p. 232-240 |
artikel |
57 |
Improving the Prediction of Response to Therapy in Autism
|
Bent, Stephen |
|
2010 |
7 |
3 |
p. 232-240 9 p. |
artikel |
58 |
Improving the Prediction of Response to Therapy in Autism
|
Bent, Stephen |
|
|
7 |
3 |
p. 232-240 |
artikel |
59 |
Medical comorbidities in autism: Challenges to diagnosis and treatment
|
Bauman, Margaret L. |
|
2010 |
7 |
3 |
p. 320-327 |
artikel |
60 |
Medical Comorbidities in Autism: Challenges to Diagnosis and Treatment
|
Bauman, Margaret L. |
|
2010 |
7 |
3 |
p. 320-327 8 p. |
artikel |
61 |
Medical Comorbidities in Autism: Challenges to Diagnosis and Treatment
|
Bauman, Margaret L. |
|
|
7 |
3 |
p. 320-327 |
artikel |
62 |
Neurotherapeutics to publish primary research papers
|
Faden, Alan I. |
|
2010 |
7 |
3 |
p. 229 |
artikel |
63 |
Neurotherapeutics to Publish Primary Research Papers
|
Faden, Alan I. |
|
2010 |
7 |
3 |
p. 229- 1 p. |
artikel |
64 |
Neurotherapeutics to Publish Primary Research Papers
|
Faden, Alan I. |
|
|
7 |
3 |
p. 229 |
artikel |
65 |
Shifting the paradigm for autism treatments
|
Hagerman, Randi J. |
|
2010 |
7 |
3 |
p. 230-231 |
artikel |
66 |
Shifting the Paradigm for Autism Treatments
|
Hagerman, Randi J. |
|
2010 |
7 |
3 |
p. 230-231 2 p. |
artikel |
67 |
Shifting the Paradigm for Autism Treatments
|
Hagerman, Randi J. |
|
|
7 |
3 |
p. 230-231 |
artikel |
68 |
Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex
|
Vries, Petrus J. de |
|
2010 |
7 |
3 |
p. 275-282 |
artikel |
69 |
Targeted Treatments for Cognitive and Neurodevelopmental Disorders in Tuberous Sclerosis Complex
|
de Vries, Petrus J. |
|
2010 |
7 |
3 |
p. 275-282 8 p. |
artikel |
70 |
Targeted Treatments for Cognitive and Neurodevelopmental Disorders in Tuberous Sclerosis Complex
|
de Vries, Petrus J. |
|
|
7 |
3 |
p. 275-282 |
artikel |
71 |
Tetrahydrobiopterin as a novel therapeutic intervention for autism
|
Frye, Richard E. |
|
2010 |
7 |
3 |
p. 241-249 |
artikel |
72 |
Tetrahydrobiopterin as a Novel Therapeutic Intervention for Autism
|
Frye, Richard E. |
|
2010 |
7 |
3 |
p. 241-249 9 p. |
artikel |
73 |
Tetrahydrobiopterin as a Novel Therapeutic Intervention for Autism
|
Frye, Richard E. |
|
|
7 |
3 |
p. 241-249 |
artikel |
74 |
Tourette syndrome: Gene expression as a tool to discover drug targets
|
Liao, Isaac H. |
|
2010 |
7 |
3 |
p. 302-306 |
artikel |
75 |
Tourette Syndrome: Gene Expression as a Tool to Discover Drug Targets
|
Liao, Isaac H. |
|
2010 |
7 |
3 |
p. 302-306 5 p. |
artikel |
76 |
Tourette Syndrome: Gene Expression as a Tool to Discover Drug Targets
|
Liao, Isaac H. |
|
|
7 |
3 |
p. 302-306 |
artikel |